ROFI, ELEONORA
 Distribuzione geografica
Continente #
NA - Nord America 2.030
EU - Europa 784
AS - Asia 606
AF - Africa 83
SA - Sud America 53
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 8
Totale 3.573
Nazione #
US - Stati Uniti d'America 1.985
IT - Italia 326
CN - Cina 245
SG - Singapore 240
SE - Svezia 122
BG - Bulgaria 78
DE - Germania 65
CI - Costa d'Avorio 58
GB - Regno Unito 52
BR - Brasile 45
CA - Canada 41
AT - Austria 31
VN - Vietnam 31
RU - Federazione Russa 28
FR - Francia 25
HK - Hong Kong 22
TR - Turchia 21
NL - Olanda 14
IN - India 13
SN - Senegal 13
ES - Italia 8
EU - Europa 8
NG - Nigeria 8
AU - Australia 7
BE - Belgio 7
JP - Giappone 6
KR - Corea 6
LT - Lituania 6
PL - Polonia 6
FI - Finlandia 4
CZ - Repubblica Ceca 3
LV - Lettonia 3
UZ - Uzbekistan 3
AR - Argentina 2
AZ - Azerbaigian 2
CH - Svizzera 2
CO - Colombia 2
LK - Sri Lanka 2
MA - Marocco 2
NZ - Nuova Zelanda 2
PA - Panama 2
PK - Pakistan 2
RO - Romania 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BD - Bangladesh 1
BO - Bolivia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
HR - Croazia 1
IL - Israele 1
IQ - Iraq 1
JO - Giordania 1
KE - Kenya 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MX - Messico 1
NO - Norvegia 1
NP - Nepal 1
PY - Paraguay 1
SA - Arabia Saudita 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 3.573
Città #
Fairfield 233
Woodbridge 218
Ashburn 197
Houston 162
Santa Clara 154
Chandler 139
Seattle 110
Cambridge 82
Serra 78
Singapore 78
Sofia 78
Wilmington 77
Ann Arbor 72
Shanghai 66
New York 59
Abidjan 58
Pisa 56
Florence 44
Princeton 42
Boardman 33
Ottawa 33
Beijing 32
Lawrence 31
Frankfurt am Main 30
Vienna 30
London 28
Medford 23
Hong Kong 22
Istanbul 19
Nanjing 19
Dearborn 18
Des Moines 16
Dong Ket 15
Boulder 14
Dakar 13
Rome 13
Chiesina Uzzanese 11
Fuzhou 11
Washington 10
Los Angeles 9
Redwood City 9
San Diego 9
Hefei 8
Lagos 8
Kunming 7
Milan 7
Bremen 6
Brussels 6
Iowa City 6
Phoenix 6
San Francisco 6
Changsha 5
Columbus 5
Düsseldorf 5
Guangzhou 5
Hyderabad 5
Lauterbourg 5
Nuremberg 5
Ogden 5
Turin 5
Kilburn 4
Quanzhou 4
Toronto 4
Belo Horizonte 3
Chengdu 3
Council Bluffs 3
Dallas 3
Genoa 3
Hebei 3
Jiaxing 3
Lancaster 3
Madrid 3
Monza 3
Nanchang 3
Norwalk 3
Pistoia 3
Prague 3
Riga 3
Shenyang 3
Warsaw 3
Zhengzhou 3
Amsterdam 2
Baku 2
Baotou 2
Bientina 2
Bitritto 2
Camaiore 2
Chicago 2
Curitiba 2
Esslingen am Neckar 2
Islamabad 2
Kolkata 2
Lucca 2
Montréal 2
Nutley 2
Perth 2
Philadelphia 2
Polska 2
Prato 2
Santiago De Compostela 2
Totale 2.660
Nome #
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 264
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 148
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 146
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients 143
null 142
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 141
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response 138
Clinical pharmacology of intravitreal anti-VEGF drugs 135
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 135
AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer 132
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World 130
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment 126
Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase. 124
Implications of KRAS mutations in acquired resistance to treatment in NSCLC 121
From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 115
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? 114
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 112
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report 111
Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment 110
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial 105
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 101
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy 98
Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring 97
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 94
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers 87
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy 85
Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells 81
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680–7 78
Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers 74
Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer 63
null 60
Should CYP2D6 be genotyped when treating with tamoxifen? 49
Should CYP2D6 be genotyped when treating with tamoxifen? [Letter in reply] 40
Totale 3.699
Categoria #
all - tutte 12.366
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.366


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202076 0 0 0 0 0 0 0 0 0 33 33 10
2020/2021238 16 18 7 17 11 12 19 14 42 15 30 37
2021/2022318 3 14 7 7 64 62 16 8 20 11 16 90
2022/2023587 59 85 45 32 49 60 1 40 148 5 61 2
2023/2024370 19 21 71 19 40 78 18 12 8 14 37 33
2024/2025760 9 38 11 70 145 119 59 55 118 136 0 0
Totale 3.699